Calpain may contribute to hereditary cataract formation in sheep.
OBJECTIVE
To determine the involvement of calpain in ovine cataractogenesis by measuring calcium, calpain activity, proteolysis, and the effect of calpain inhibition.


METHODS
Sheep with genetic cataracts were examined for cataract severity. Calcium in normal and cataract lenses was measured. The presence of calpain was detected by casein zymography and immunoblotting. Calpain activity was assayed using BODIPY-casein as a substrate. Degradation of calpain substrates spectrin and vimentin was assessed by immunoblotting. The calpain inhibitor SJA6017 was applied to the left eye of cataract lambs, leaving the right eye as an untreated control. Both eyes were monitored by slit-lamp microscopy for cataract progression.


RESULTS
Cortical cataracts were first observed in lambs at 1 to 2 months of age. Lens calcium concentration increased in the early stages of cataract formation and was >10-fold higher in mature cataract than normal lenses. Three calpain isoforms were detected in young lamb lenses. Calpain activity decreased as cataracts progressed. Both spectrin and vimentin were degraded with cataract maturity, which could indicate calpain proteolysis. Cataract lambs treated with SJA6017 eyedrops over a period of 4 months showed significantly smaller cataracts in the left treated eye over the right untreated eye.


CONCLUSIONS
The presence of calpains and calcium elevation during cataract formation suggests that proteolysis may play a role in opacification in ovine lens. This hypothesis is supported by the delay in opacification with SJA6017 treatment. The results also suggested that the ovine hereditary cataract is a useful nonrodent model to test the role of calpains in cataractogenesis.
Robertson
Lucinda J G
LJ
Agriculture and Life Sciences, Lincoln University, Canterbury, New Zealand. roberl@lincoln.ac.nz
Morton
James D
JD
Yamaguchi
Masazumi
M
Bickerstaffe
Roy
R
Shearer
Thomas R
TR
Azuma
Mitsuyoshi
M
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D002154:Calpain / Q000037:antagonists & inhibitors / Q000502:physiology*; D002386:Cataract / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology / Q000662:veterinary*; D015853:Cysteine Proteinase Inhibitors / Q000008:administration & dosage; D004151:Dipeptides / Q000008:administration & dosage; D004591:Electrophoresis, Polyacrylamide Gel / Q000662:veterinary; D005260:Female; D006023:Glycoproteins / Q000008:administration & dosage; D007908:Lens, Crystalline / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D012756:Sheep; D012757:Sheep Diseases / Q000235:genetics* / Q000378:metabolism / Q000503:physiopathology
D001786:Blood Glucose; D015853:Cysteine Proteinase Inhibitors; D004151:Dipeptides; D006023:Glycoproteins; C109145:N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal; D009883:Ophthalmic Solutions; C039304:calpain inhibitors; D002154:Calpain; D002118:Calcium